For over twenty years, Swedish Orphan International’s commitment to patients with rare disorders has gone hand in hand with healthy financial growth. The company has grown steadily with good profitability making it possible to invest in making available an increasing number of orphan drugs for an increasing number of rare disease patients. With such a past, we look to the future with confidence.

1988 Swedish Orphan International AB is established in Sweden.

1995 Oy Swedish Orphan is established in Finland.

1996 Swedish Orphan A/S is established in Denmark.

1996 Swedish Orphan AS is established in Norway.

1998 Swedish Orphan KK is founded in Japan.

1999 Swedish Orphan AB is established.

2002 Swedish Orphan International Ltd. is established in the UK.

2002 Orfadin is approved for sale in the USA.

2004 Swedish Orphan International Holding AB is acquired by Investor Growth Capital and Skandia Investment. The company is also owned by the SOI management.

2005 Orfadin is approved for sale throughout the EU.

2006 Swedish Orphan International establishes offices in Italy, Spain, Germany and France. Metcon Medicine, a pharmaceutical company, is acquired.

2007 Swedish Orphan International establishes an office in the Czech Republic.

2008 Swedish Orphan International establishes an office in Russia and now covers all of Europe from the new offices abroad. The company acquires licenses for 14 new drugs.

2009 Multiferon® is approved in another 14 European Countries.